In the News | Charles River

   
 
 
   
   

Getting a Handle on Metabolic Disorders
Targets and Methods Vary, but the End-Goal Is the Same – More Effective Therapeutics
Genetic Engineering News - April 1, 2009

IBC’s “Targeting Metabolic Disorders” meeting, held late last month in Boston, was particularly timely given the new regulatory hurdles and higher standards for efficacy required for the next generation of metabolic drug products. Most of the presenters were confident that their research efforts would ultimately lead to the development of better metabolic therapeutics.

Representing Metabolex, Maria Wilson, Ph.D., senior scientist, and Charles McWherter, Ph.D., senior vp of research and preclinical development, discussed the company’s ongoing research. Dr. Wilson specifically reviewed her work with the GPR119 agonist MBX-2982, a drug candidate in Phase I development...Read the full article.

   
Discover the full range of Charles River Products and Services

For more information please call:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
Sep 02 - P. carinii Pinpointed as Causative...
Aug 16 - ZDF Rat Diet Update
Oct 10-Oct 14 - Atlanta, GA - 61st AALAS National Meeting
Sep 20-Sep 23 - Boston, MA - Safety Pharmacology Society Annual Meeting
Sep 13-Sep 15 - San Diego, CA - 16th Annual Symposium on Biotechnology-Derived Therapeu...
view all
Manager Corporate Consolidation Wilmingto...
Director, Clinical Specialist Sales 
IT Specialist II - Web Development  
Senior Tax Analyst Wilmington, MA

Charles River Laboratories, Inc.